Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

TALTZ 80 MG/ML SYRINGE

ixekizumab
$7402.0700per ML

Strength

80 mg/mL

Manufacturer

Eli Lilly and Company

NDC

00002772411

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

1/1/2026

Active Ingredients

IXEKIZUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA125521

On Market Since

3/22/2016

Pharmacological Classes

Interleukin-17A Antagonist
Interleukin-17A Antagonists

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.0%

1Y

+5.0%

3Y

N/A

5Y

N/A

All

+10.4%

Generic Alternatives

Save up to 1%

1 alternative • Same active ingredient

TALTZ 80 MG/ML AUTOINJECTOR
Brand
00002144511•Eli Lilly and Company
$7347.5448
Save 1%

Related Drugs

Same classification

COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)
Brand
00078063941•Novartis Pharmaceuticals Corporation
$3950.7728
per ML
COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES
Brand
00078063998•Novartis Pharmaceuticals Corporation
$3965.6440
per ML
COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)
Brand
00078107068•Novartis Pharmaceuticals Corporation
$4105.5041
per ML
COSENTYX SENSOREADY 150 MG/ML PEN
Brand
00078063968•Novartis Pharmaceuticals Corporation
$7874.0281
per ML
COSENTYX 150 MG/ML SYRINGE
Brand
00078063997•Novartis Pharmaceuticals Corporation
$7923.3134
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy